Time for a gut check: Pancreatic sufficiency resulting from CFTR modulator use
Related Experiment Video
Updated: Jan 25, 2026

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
Published on: March 9, 2015
Rosemary Megalaa1, Vani Gopalareddy2, Elizabeth Champion1
1Division of Pediatric Pulmonology, Atrium Health, Levine Children's Hospital, Charlotte, NC.
Insights
Pancreatic exocrine insufficiency in cystic fibrosis may improve with treatment. A 10-year-old child regained pancreatic function after 4 years on ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator.
Area of Science:
- Medical Research
- Genetics
- Pediatrics
Background:
- Pancreatic exocrine insufficiency (PEI) is a common complication of cystic fibrosis (CF), often considered irreversible.
- Genetic factors determine PEI in CF, impacting digestion and nutrient absorption.
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators are emerging therapies for CF.
Observation:
- A 10-year-old patient presented with lifelong PEI since birth.
- The patient was treated with ivacaftor, a CFTR corrector drug, for four years.
- Pancreatic function was assessed over the treatment period.
Findings:
- The patient demonstrated a significant regain of pancreatic exocrine function after four years of ivacaftor therapy.
- This suggests that pancreatic function in CF may not be entirely irreversible, even in cases of long-standing insufficiency.
- CFTR modulator therapy showed potential for restoring pancreatic function.
Implications:
- This case highlights the potential for CFTR modulators to reverse or improve pancreatic exocrine function in cystic fibrosis patients.
- It suggests a possible therapeutic window for intervention, even in individuals with PEI since birth.
- Further research is warranted to explore the long-term effects and mechanisms of CFTR modulators on pancreatic function in CF.
Abstract:
Pancreatic exocrine insufficiency in cystic fibrosis is genetically determined and generally felt to be irreversible. However, recent studies in young children started on cystic fibrosis transmembrane conductance regulator (CFTR) modulators have suggested improvement of pancreatic functioning over time. Here, we present the case of a 10-year-old child with pancreatic exocrine insufficiency since birth who regained pancreatic functioning after 4 years on the CFTR corrector drug, ivacaftor.
Related Concept Videos
Protein Folding Quality Check in the RER
Pancreatic Juice and Secretion
When acidic chyme from the stomach enters the duodenum, it triggers the release of secretin, a hormone that prompts pancreatic juice secretion. After a fatty meal, cholecystokinin, another hormone, stimulates gallbladder contraction and enhances enzyme-rich...
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Physiology of Enteric Nervous System and Gut Health
Chronic Pancreatitis II: Collaborative Care
Assessment:

